Background Resistance to anti-malarials is a major threat to the control and elimination of
malaria. Sulfadoxine–pyrimethamine (SP) anti-malarial treatment was used as a national …

Plasmodium falciparum, the protozoan that causes the most lethal form of human malaria,
has been controlled principally by two safe, affordable drugs, chloroquine and sulfadoxine …

Since the late 1970s pyrimethamine-sulfadoxine (PS; FansidarTM Hoffman-LaRoche, Basel)
has been used as first line therapy for uncomplicated malaria in the Amazon basin …

The Plasmodium falciparum dihydrofolate reductase (PfDHFR) enzyme is the target of
pyrimethamine, a component of the antimalarial pyrimethamine-sulfadoxine. Resistance to …

The antifolate drugs sulfadoxine and pyrimethamine are commonly used to treat
Plasmodium falciparum malaria. However, they can also affect the Plasmodium vivax …

Background Plasmodium falciparum is the predominant human malaria species in
Mozambique and a lead cause of mortality among children and pregnant women …

Analysis of the molecular basis of antimalarial drug resistance has demonstrated that
mutations in the dihydrofolate reductase (dhfr) and dihydropteroate synthase genes are …

Dihydropteroate synthase (DHPS) is a known sulfa drug target in malaria treatment, existing
as a bifunctional enzyme together with hydroxymethyldihydropterin pyrophosphokinase …

Genotyping the sulfadoxine–pyrimethamine (SP) genes will help in identifying the genes
under drug selection and the emergence of resistance in dhfr and dhps genes. India is an …

Senegal recently (2004) switched to sulfadoxine‐pyrimethamine (SP) with amodiaquine as
first line therapy for malaria in response to increasing chloroquine resistance. In anticipation …